-
1
Antibodies against the multifaceted cathepsin D protein open new avenues for TNBC immunotherapy
Published 2025-01-01“…Triple-negative breast cancer (TNBC) is a heterogeneous breast cancer subtype characterized by aggressive clinical behavior and poor prognosis. …”
Get full text
Article -
2
Exploring the role of metabolic pathways in TNBC immunotherapy: insights from single-cell and spatial transcriptomics
Published 2025-01-01“…The article provides an overview of the current understanding of the interplay between metabolic pathways and immune function in the context of triple-negative breast cancer (TNBC). It highlights recent advancements in single-cell and spatial transcriptomics technologies, which have revolutionized the analysis of tumor heterogeneity and the immune microenvironment in TNBC. …”
Get full text
Article -
3
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms
Published 2025-02-01Subjects: “…Triple negative breast cancer (TNBC)…”
Get full text
Article -
4
A select inhibitor of MORC2 encapsulated by chimeric membranecoated DNA nanocage target alleviation TNBC progression
Published 2025-04-01“…In this study, bioinformatic analysis and a series of experiments demonstrated that MOCR2 was highly expressed in TNBC and closely associated with poor prognosis, indicating that MOCR2 may be a potential therapeutic target for TNBC. …”
Get full text
Article -
5
Twist-Induced Epithelial-to-Mesenchymal Transition Confers Specific Metabolic and Mitochondrial Alterations
Published 2025-01-01Subjects: Get full text
Article -
6
Unraveling the protein kinase C/NDRG1 signaling network in breast cancer
Published 2024-12-01Subjects: Get full text
Article -
7
Anti-TNBC effects of Lappaol F by targeting epithelial-mesenchymal transition via regulation of GSK-3β/YAP/β-catenin and PI3K/AKT pathways
Published 2025-02-01“…PurposeLappaol F (LAF), a lignan extracted from Fructus Arctii, has a wide spectrum of anti-tumor effects, including inhibition of TNBC cell growth. However, the pharmacological mechanism of LAF targeting epithelial-mesenchymal transition (EMT) to inhibit Triple-negative breast cancer (TNBC) growth remains poorly understood. …”
Get full text
Article -
8
Uncarboxylated osteocalcin induced miR-143-3p targets SP7 and activates PI3K/Akt signaling in TNBC cells to promote invasion and migration
Published 2025-03-01Subjects: Get full text
Article -
9
Pharmacological activity of OST-01, a natural product from baccharis coridifolia, on breast cancer cells
Published 2025-02-01Subjects: “…TNBC…”
Get full text
Article -
10
Proteomic profiling identifies upregulation of aurora kinases causing resistance to taxane-type chemotherapy in triple negative breast cancer
Published 2025-01-01Subjects: “…TNBC…”
Get full text
Article -
11
-
12
Exploring target selectivity in designing and identifying PI3Kα inhibitors for triple negative breast cancer with fragment-based and bioisosteric replacement approach
Published 2025-01-01Subjects: “…TNBC…”
Get full text
Article -
13
The association between sarcopenia and clinical outcomes among Chinese patients with triple-negative breast cancer: a retrospective study
Published 2025-02-01Subjects: Get full text
Article -
14
LURAP1L-AS1 long noncoding RNA promotes breast cancer progression and associates with poor prognosis
Published 2025-06-01Subjects: Get full text
Article -
15
Inosine monophosphate dehydrogenase 2 (IMPDH2) modulates response to therapy and chemo-resistance in triple negative breast cancer
Published 2025-01-01Subjects: “…TNBC…”
Get full text
Article -
16
Research on therapeutic clinical trials including immunotherapy in triple-negative breast cancer: a bibliometric analysis
Published 2024-10-01Subjects: Get full text
Article -
17
Inhibition of triple-negative breast cancer growth via delphinidin-mediated suppression of the JAK2/STAT3/PD-L1 pathway
Published 2024-12-01Subjects: Get full text
Article -
18
-
19
-
20